Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case Studies Witfire Elite View Lumvoa Broke Tepezza’s Monopoly Now Viridian Has to Prove It Can Sell Viridian’s Lumvoa approval is not only a new thyroid eye disease launch. It is…
Trending News
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology…
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Editorial picks
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case Studies Witfire Elite View Lumvoa Broke Tepezza’s Monopoly Now Viridian Has to Prove It Can Sell Viridian’s Lumvoa approval is…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Japan Pharma Long Read Pharma Market Case Studies Witfire Elite View Tanabe’s Uplizna Defense Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence…
Pharma News
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire…
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case…
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case…